{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:54:34Z","timestamp":1788980074166,"version":"build-2803163510"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473854"],"award-info":[{"award-number":["82473854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.addr.2026.115773","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:41:08Z","timestamp":1767976868000},"page":"115773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease"],"prefix":"10.1016","volume":"230","author":[{"given":"Shuqian","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2026.115773_bb0005","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1038\/s41467-023-43036-1","article-title":"A large meta-analysis identifies genes associated with anterior uveitis","volume":"14","author":"Gelfman","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115773_bb0010","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41433-020-01339-3","article-title":"Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance","volume":"35","author":"Ting","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/eye.2017.289","article-title":"Assessment and management of dry eye disease","volume":"32","author":"Buckley","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","article-title":"Current understanding of the molecular and cellular pathology of diabetic retinopathy","volume":"17","author":"Antonetti","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2026.115773_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2026.115773_bb0030","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/nrdp.2016.67","article-title":"Primary open-angle glaucoma","volume":"2","author":"Weinreb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.addr.2026.115773_bb0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/eye.2016.315","article-title":"Seeing through their eyes: lived experiences of people with retinitis pigmentosa","volume":"31","author":"Prem Senthil","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0040","first-page":"e1221","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis, Lancet Glob","volume":"5","author":"Flaxman","year":"2017","journal-title":"Health"},{"key":"10.1016\/j.addr.2026.115773_bb0045","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1517\/17425247.2015.1021680","article-title":"Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics","volume":"12","author":"Hartnett","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2026.115773_bb0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1364\/AO.10.000459","article-title":"Theory of transparency of the eye","volume":"10","author":"Benedek","year":"1971","journal-title":"Appl. Opt."},{"key":"10.1016\/j.addr.2026.115773_bb0055","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/eye.2008.21","article-title":"Adult vitreous structure and postnatal changes","volume":"22","author":"Le Goff","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202204283","article-title":"Colloidal Polyelectrolyte Complexes from Hyaluronic Acid: Preparation and Biomedical Applications","volume":"18","author":"Le","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.addr.2026.115773_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.preteyeres.2005.10.001","article-title":"The lens of the eye as a focusing device and its response to stress","volume":"25","author":"Banh","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0070","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/sj.eye.6701578","article-title":"A history of the optic nerve and its diseases","volume":"18","author":"Reeves","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0075","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.preteyeres.2009.12.002","article-title":"The multifunctional choroid","volume":"29","author":"Nickla","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular Drug Delivery: a Comprehensive Review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115773_bb0085","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115773_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114870","article-title":"Recent advances and future prospects: Current status and challenges of the intraocular injection of drugs for vitreoretinal diseases","volume":"198","author":"Hashida","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.preteyeres.2012.10.004","article-title":"A contemporary concept of the blood-aqueous barrier","volume":"32","author":"Freddo","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0039-6257(79)90158-9","article-title":"The blood-ocular barriers","volume":"23","author":"Cunha-Vaz","year":"1979","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2012.0200","article-title":"Novel strategies for anterior segment ocular drug delivery","volume":"29","author":"Cholkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201803239","article-title":"Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy","volume":"14","author":"Dillinger","year":"2018","journal-title":"Small"},{"issue":"Suppl. 6","key":"10.1016\/j.addr.2026.115773_bb0115","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier","volume":"21","author":"Cunha-Vaz","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0120","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/febs.16330","article-title":"The blood-retina barrier in health and disease","volume":"290","author":"O'Leary","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.addr.2026.115773_bb0125","doi-asserted-by":"crossref","first-page":"15296","DOI":"10.1038\/ncomms15296","article-title":"Plastic roles of pericytes in the blood-retinal barrier","volume":"8","author":"Park","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115773_bb0130","first-page":"219","article-title":"Systemic Drug Delivery to the Posterior Segment of the Eye: Overcoming Blood\u2013Retinal Barrier Through Smart Drug Design and Nanotechnology","author":"Ranganath","year":"2020","journal-title":"Gels Horizons: From Science to Smart Materials"},{"key":"10.1016\/j.addr.2026.115773_bb0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4419-9920-7_4","article-title":"Systemic Route for Retinal Drug Delivery: Role of the Blood-Retinal Barrier","author":"Tachikawa","year":"2011","journal-title":"AAPS Advances in the Pharmaceutical Sciences Series"},{"key":"10.1016\/j.addr.2026.115773_bb0140","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00417-014-2764-6","article-title":"Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials","volume":"252","author":"Kodjikian","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0145","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2026.115773_bb0150","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0155","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40123-025-01181-4","article-title":"Functional and Anatomical Outcomes of Faricimab in Previously Treated Wet Age-Related Macular Degeneration: Systematic Review and Pooled Analysis","volume":"14","author":"Khodor","year":"2025","journal-title":"Ophthalmol Therapy"},{"key":"10.1016\/j.addr.2026.115773_bb0160","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0014-4835(84)90078-2","article-title":"A simple method of measuring aqueous humor flow with intravitreal fluoresceinated dextrans","volume":"39","author":"Johnson","year":"1984","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0165","article-title":"The Trabecular Meshwork: A Basic Review of Form and Function","volume":"2","author":"Abu-Hassan","year":"2014","journal-title":"J Ocul Biol"},{"key":"10.1016\/j.addr.2026.115773_bb0170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0014-4835(92)90121-8","article-title":"Aspects of the development of Schlemm's canal","volume":"55","author":"Hamanaka","year":"1992","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb0180","series-title":"Drug Product Development for the Back of the Eye","first-page":"125","article-title":"Principles of Retinal Drug Delivery from Within the Vitreous","author":"Wilson","year":"2011"},{"key":"10.1016\/j.addr.2026.115773_bb0185","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0190","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1021\/acs.molpharmaceut.0c01218","article-title":"Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats","volume":"18","author":"Jakubiak","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.008","article-title":"Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation","volume":"143","author":"Ramsay","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2026.115773_bb0200","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s11095-008-9728-7","article-title":"Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR)","volume":"26","author":"Durairaj","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115773_bb0205","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","article-title":"Ranibizumab","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115773_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10632","article-title":"A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration","volume":"9","author":"Huang","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2026.115773_bb0215","article-title":"Long-Acting Ocular Injectables: Are We Looking In The Right Direction?","volume":"11","author":"Dang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.addr.2026.115773_bb0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti\u2013Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0225","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yaoo.2023.02.010","article-title":"Evolution and Advances in Wet Age-Related Macular Degeneration Treatments","volume":"8","author":"Goldburg","year":"2023","journal-title":"Advances in Ophthalmology and Optometry"},{"key":"10.1016\/j.addr.2026.115773_bb0230","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/IJG.0000000000001894","article-title":"Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations","volume":"30","author":"Levin","year":"2021","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.addr.2026.115773_bb0235","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","article-title":"Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment","volume":"133","author":"Bressler","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.addr.2026.115773_bb0240","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0245","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0250","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0255","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115773_bb0260","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model","volume":"57","author":"Park","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0265","article-title":"KSI-301: antibody biopolymer conjugate in retinal disorders","volume":"13","author":"Chandrasekaran","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.addr.2026.115773_bb0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/13543784.2022.2052042","article-title":"KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases","volume":"31","author":"Stern","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.addr.2026.115773_bb0275","doi-asserted-by":"crossref","first-page":"12620","DOI":"10.1039\/D1CP00954K","article-title":"Understanding the role of hydrophobic patches in protein disaggregation","volume":"23","author":"Kumar","year":"2021","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.addr.2026.115773_bb0280","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/137740a0","article-title":"Determination of Particle Weight and Shape from Diffusion and Viscosity Data","volume":"137","author":"Polson","year":"1936","journal-title":"Nature"},{"key":"10.1016\/j.addr.2026.115773_bb0285","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0014-3057(84)90080-6","article-title":"Dependence of viscosity of polystyrene solutions on molecular weight and concentration","volume":"20","author":"Poh","year":"1984","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.addr.2026.115773_bb0290","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-5173(95)04404-3","article-title":"The effect of molecular weight on the rheological and tensile properties of poly(\u03b5-caprolactone)","volume":"135","author":"Grosvenor","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0295","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00397-009-0402-8","article-title":"Influence of dispersion procedure on rheological properties of aqueous solutions of high molecular weight PEO","volume":"49","author":"Bossard","year":"2009","journal-title":"Rheol. Acta"},{"key":"10.1016\/j.addr.2026.115773_bb0300","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0305","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0310","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","volume":"32","author":"Stewart","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115773_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb0320","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0325","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0330","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","article-title":"Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit","volume":"97","author":"Li","year":"2012","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0335","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12886-018-0807-1","article-title":"Conbercept for patients with age-related macular degeneration: a systematic review","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100467","article-title":"Bispecific VEGF-A and Angiopoietin-2 Antagonist RO-101 Preclinical Efficacy in Model of Neovascular Eye Disease","volume":"4","author":"Xu","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.addr.2026.115773_bb0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.21037\/aes-21-41","article-title":"Molecular structure, pharmacokinetics and clinical evidence of brolucizumab: a narrative review","volume":"6","author":"Pignatelli","year":"2021","journal-title":"Annals of Eye Science"},{"key":"10.1016\/j.addr.2026.115773_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010205","article-title":"Ocular Delivery of Therapeutic Proteins: A Review","volume":"15","author":"Shastri","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb0355","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115773_bb0360","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115773_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-002091","article-title":"Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series","volume":"10","author":"Sambhara","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.addr.2026.115773_bb0370","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the development of high protein concentration formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0375","doi-asserted-by":"crossref","first-page":"2211185","DOI":"10.1080\/19420862.2023.2211185","article-title":"High concentration formulation developability approaches and considerations","volume":"15","author":"Zarzar","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115773_bb0380","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coche.2017.04.001","article-title":"Recent progresses of understanding the viscosity of concentrated protein solutions","volume":"16","author":"Zhang","year":"2017","journal-title":"Current Opinion in Chemical Engineering"},{"key":"10.1016\/j.addr.2026.115773_bb0385","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1021\/acs.molpharmaceut.5b00643","article-title":"Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0390","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1021\/acs.molpharmaceut.9b00687","article-title":"Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering","volume":"16","author":"Xu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0395","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1021\/mp200566k","article-title":"The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions","volume":"9","author":"Yadav","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0400","doi-asserted-by":"crossref","first-page":"2304282","DOI":"10.1080\/19420862.2024.2304282","article-title":"Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG(1) antibody","volume":"16","author":"Dai","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115773_bb0405","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4161\/19420862.2014.985504","article-title":"Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions","volume":"7","author":"Nichols","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.addr.2026.115773_bb0410","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0268-005X(01)00129-1","article-title":"Effects of sucrose and sorbitol on the gel formation of a whey protein isolate","volume":"16","author":"Dierckx","year":"2002","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.addr.2026.115773_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2021.106733","article-title":"Differential effect of polyol and sugar osmolytes on the refolding of homologous alpha amylases: A comparative study","volume":"281","author":"Ahmad","year":"2022","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.addr.2026.115773_bb0420","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/mp5000218","article-title":"Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations","volume":"11","author":"Inoue","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126058","article-title":"Long acting injectables & implants: advances in intraocular drug delivery","volume":"683","author":"Cuello-Rodr\u00edguez","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/v17020239","article-title":"Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy","volume":"17","author":"Zwi-Dantsis","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.addr.2026.115773_bb0450","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s42399-025-01971-8","article-title":"Revolutionizing Diabetic Macular Edema Treatment: FDA Approval of Susvimo","volume":"7","author":"Kumar","year":"2025","journal-title":"SN Comprehensive Clinical Medicine"},{"key":"10.1016\/j.addr.2026.115773_bb0460","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2022.03.005","article-title":"In-vitro characterization of ranibizumab release from the Port Delivery System","volume":"345","author":"Yohe","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2026.115773_bb0465","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0470","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaophthalmol.2025.0006","article-title":"Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial","volume":"143","author":"Khanani","year":"2025","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0475","first-page":"6233","article-title":"Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial","volume":"65","author":"Malhotra","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0480","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaophthalmol.2025.0001","article-title":"Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial","volume":"143","author":"Pieramici","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.addr.2026.115773_bb0485","first-page":"2188","article-title":"Long-term efficacy and safety of the Port Delivery System with ranibizumab in patients with neovascular age-related macular degeneration: Results from the Portal 5-year subgroup analysis","volume":"64","author":"Howard","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0490","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0495","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40942-023-00446-z","article-title":"Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists","volume":"9","author":"Sharma","year":"2023","journal-title":"International Journal of Retina and Vitreous"},{"key":"10.1016\/j.addr.2026.115773_bb0500","first-page":"506","article-title":"NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells","volume":"10","author":"Emerich","year":"2008","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb0505","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11530970-000000000-00000","article-title":"Biodegradable intraocular therapies for retinal disorders: progress to date","volume":"27","author":"Kuno","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.addr.2026.115773_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107159","article-title":"Encapsulated cell technology: Delivering cytokines to treat posterior ocular diseases","volume":"203","author":"Wang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2026.115773_bb0515","series-title":"Neurotech\u2019s ENCELTO\u2122 (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)","year":"2026"},{"key":"10.1016\/j.addr.2026.115773_bb0520","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial","volume":"126","author":"Chew","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0525","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1018987108","article-title":"Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration","volume":"108","author":"Zhang","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0530","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","article-title":"Randomized Trial of Ciliary Neurotrophic Factor Delivered by Encapsulated Cell Intraocular Implants for Retinitis Pigmentosa","volume":"156","author":"Birch","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0535","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1167\/iovs.12-9970","article-title":"Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases","volume":"53","author":"Kauper","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0540","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400481","article-title":"Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2","volume":"4","author":"Chew","year":"2025","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.addr.2026.115773_bb0545","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115773_bb0550","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb0555","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/4768","article-title":"\u03b1V\u03b25 integrin: a co-receptor for adeno-associated virus type 2 infection","volume":"5","author":"Summerford","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2026.115773_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 Implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0565","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jsb.2008.12.002","article-title":"Heparin binding induces conformational changes in Adeno-associated virus serotype 2","volume":"165","author":"Levy","year":"2009","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.addr.2026.115773_bb0570","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.addr.2026.115773_bb0575","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","article-title":"AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies","volume":"38","author":"Castro","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115773_bb0580","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","article-title":"Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb0585","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115773_bb0590","first-page":"419","article-title":"Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting","volume":"65","author":"Sahel","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0595","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice","volume":"38","author":"Testa","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0600","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jval.2025.04.226","article-title":"CO141 Evaluating the Impact of Luxturna Gene Therapy on Vision Improvement and Disease Progression in Patients With RPE65 Mutation-Associated Inherited Vision Loss","volume":"28","author":"Kukreja","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.addr.2026.115773_bb0605","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115773_bb0610","series-title":"Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value. Final evidence report","author":"Review","year":"2018"},{"key":"10.1016\/j.addr.2026.115773_bb0615","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12913-022-08211-y","article-title":"Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland","volume":"22","author":"Bhadhuri","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.addr.2026.115773_bb0620","series-title":"GenSight Biologics Withdraws its EMA","year":"2023"},{"key":"10.1016\/j.addr.2026.115773_bb0625","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115773_bb0630","first-page":"4356","article-title":"Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration","volume":"65","author":"Khanani","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0635","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ophtha.2024.06.013","article-title":"Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration","volume":"131","author":"Heier","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0640","first-page":"2295","article-title":"GT005, a gene therapy for the treatment of dry age-related macular degeneration (AMD)","volume":"61","author":"Ellis","year":"2020","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/TACG.S383453","article-title":"Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?, Appl","volume":"16","author":"Ail","year":"2023","journal-title":"Clin. Genet."},{"key":"10.1016\/j.addr.2026.115773_bb0650","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2026.115773_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb0660","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb0665","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41433-025-03856-5","article-title":"A viewpoint about Lenadogene nolparvovec failing to meet its primary endpoint even though it permanently corrects the m.11778G>A mutation causative of LHON","volume":"39","author":"Panfoli","year":"2025","journal-title":"Eye"},{"key":"10.1016\/j.addr.2026.115773_bb0670","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajo.2008.12.033","article-title":"Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome","volume":"147","author":"Williams","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.addr.2026.115773_bb0675","first-page":"28","article-title":"Polymers for Retinal Drug Delivery","volume":"20","author":"Charles","year":"2023","journal-title":"Retin. Physician"},{"key":"10.1016\/j.addr.2026.115773_bb0680","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/eye.2017.125","article-title":"Real-world experience with 0.2\u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom","volume":"31","author":"Bailey","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.addr.2026.115773_bb0685","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2026.115773_bb0690","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2147\/DDDT.S506520","article-title":"Bimatoprost Intracameral Implant (Durysta\u00ae): A New Era in Glaucoma Management Through Sustained-Release Innovation","volume":"19","author":"Vagiakis","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.addr.2026.115773_bb0695","first-page":"627","article-title":"Rate of bimatoprost implant biodegradation in the phase 3 ARTEMIS studies","volume":"62","author":"Brubaker","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0700","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1039\/D3AN01739G","article-title":"Advanced manufacturing of nanoparticle formulations of drugs and biologics using microfluidics","volume":"149","author":"Shen","year":"2024","journal-title":"Analyst"},{"key":"10.1016\/j.addr.2026.115773_bb0705","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1021\/mp200608y","article-title":"Mapping microclimate pH distribution inside protein-encapsulated PLGA microspheres using confocal laser scanning microscopy","volume":"9","author":"Liu","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0710","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2219864","article-title":"Rationalized design to explore the full potential of PLGA microspheres as drug delivery systems","volume":"30","author":"Martinez-Borrajo","year":"2023","journal-title":"Drug Delivery"},{"key":"10.1016\/j.addr.2026.115773_bb0715","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/foods13081177","article-title":"Preparation and Characterization of a Hypoglycemic Complex of Gallic Acid\u2013Antarctic Krill Polypeptide Based on Polylactic Acid\u2013Hydroxyacetic Acid (PLGA) and High-Pressure Microjet Microencapsulation","volume":"13","author":"Li","year":"2024","journal-title":"Foods"},{"key":"10.1016\/j.addr.2026.115773_bb0720","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.drudis.2019.05.037","article-title":"Hydrogels for sustained delivery of biologics to the back of the eye","volume":"24","author":"Chang","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2026.115773_bb0725","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40265-020-01344-6","article-title":"Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2026.115773_bb0730","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/OPTH.S448973","article-title":"Early Real-World Patient and Staff Experience with an Intracanalicular Dexamethasone Insert","volume":"18","author":"Nijm","year":"2024","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.addr.2026.115773_bb0735","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tips.2021.01.005","article-title":"Affinity Hydrogels for Protein Delivery","volume":"42","author":"Abune","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0740","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1021\/cr200157d","article-title":"Hydrogels for Protein Delivery","volume":"112","author":"Vermonden","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb0745","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijpharm.2015.05.071","article-title":"An injectable thermosensitive polymeric hydrogel for sustained release of Avastin\u00ae to treat posterior segment disease","volume":"490","author":"Xie","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0750","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/02713683.2018.1533983","article-title":"Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro","volume":"44","author":"Liu","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2020.110258","article-title":"Cellulose nanocomposite modified conductive self-healing hydrogel with enhanced mechanical property","volume":"146","author":"Yue","year":"2021","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.addr.2026.115773_bb0760","article-title":"Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye","volume":"106","author":"Kang Derwent","year":"2008","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.addr.2026.115773_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107071","article-title":"Impact of protein adsorption during biopharmaceutical manufacture & storage","volume":"209","author":"Downey","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0770","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1039\/D3CC04311H","article-title":"Interface-mediated protein aggregation","volume":"59","author":"Tao","year":"2023","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2026.115773_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118608","article-title":"Protein-protein interactions and water activity coefficients can be used to aid a first excipient choice in protein formulations","volume":"569","author":"Schleinitz","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0780","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5731\/pdajpst.2020.012120","article-title":"An Investigation to Examine the Effect of the Elastomeric Surface Treatment on Protein Stability","volume":"75","author":"Singh","year":"2021","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115773_bb0785","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.xphs.2022.01.011","article-title":"Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality","volume":"111","author":"Narhi","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0790","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5731\/pdajpst.2016.007146","article-title":"A comparison of protein stability in prefillable syringes made of glass and plastic","volume":"71","author":"Waxman","year":"2017","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2026.115773_bb0795","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.xphs.2018.01.021","article-title":"Sweeping of Adsorbed Therapeutic Protein on Prefillable Syringes Promotes Micron Aggregate Generation","volume":"107","author":"Maruno","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0800","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.fct.2014.06.022","article-title":"The binding affinity of phthalate plasticizers-protein revealed by spectroscopic techniques and molecular modeling","volume":"71","author":"Yue","year":"2014","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.addr.2026.115773_bb0805","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-024-00988-6","article-title":"Interference of Plasticizers on Plasma Protein Binding Measurements","volume":"27","author":"Harrison","year":"2024","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115773_bb0810","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1208\/s12248-018-0276-8","article-title":"Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs","volume":"21","author":"Ingram","year":"2018","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2026.115773_bb0815","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/jcis.1997.4841","article-title":"Adsorption of a Formulated Protein on a Drug Delivery Device Surface","volume":"189","author":"Tzannis","year":"1997","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0820","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cis.2010.12.007","article-title":"Understanding protein adsorption phenomena at solid surfaces","volume":"162","author":"Rabe","year":"2011","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0825","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41565-023-01584-z","article-title":"Controlled adsorption of multiple bioactive proteins enables targeted mast cell nanotherapy","volume":"19","author":"Du","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2026.115773_bb0830","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/ma14071590","article-title":"Titanium and Protein Adsorption: An Overview of Mechanisms and Effects of Surface Features","volume":"14","author":"Barberi","year":"2021","journal-title":"Materials"},{"key":"10.1016\/j.addr.2026.115773_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.110992","article-title":"Fundamental Principles of the Thermodynamics and Kinetics of Protein Adsorption to Material Surfaces","volume":"191","author":"Latour","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.addr.2026.115773_bb0840","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cocis.2019.02.001","article-title":"Protein interactions with negatively charged inorganic surfaces","volume":"41","author":"Kubiak-Ossowska","year":"2019","journal-title":"Current Opinion in Colloid & Interface Science"},{"key":"10.1016\/j.addr.2026.115773_bb0845","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.addr.2017.01.003","article-title":"Design control considerations for biologic-device combination products","volume":"112","author":"Anderson","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb0850","first-page":"685","article-title":"Risk Management in Drug-Device Combination Product Development, Therapeutic Innovation & Regulatory","volume":"56","author":"Kumoluyi","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115773_bb0855","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0860","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2015.07.054","article-title":"Calculation of injection forces for highly concentrated protein solutions","volume":"493","author":"Fischer","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0865","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.addr.2011.09.008","article-title":"Viscosity of concentrated therapeutic protein compositions","volume":"63","author":"Jezek","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195788","article-title":"Understanding the Adsorption of Peptides and Proteins onto PEGylated Gold Nanoparticles","volume":"26","author":"Perera","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115773_bb0875","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1021\/acs.molpharmaceut.4c01132","article-title":"Effect of PEGylation on the Adsorption and Binding Strength of Plasma Proteins to Nanoparticle Surfaces","volume":"22","author":"Lee","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.tifs.2024.104374","article-title":"Zwitterions modified biosensors improve detection performance in complex food matrices","volume":"145","author":"Zhang","year":"2024","journal-title":"Trends in Food Science & Technology"},{"key":"10.1016\/j.addr.2026.115773_bb0885","doi-asserted-by":"crossref","first-page":"39104","DOI":"10.1021\/acsami.4c07752","article-title":"Stability Enhancement by Hydrophobic Anchoring and a Cross-Linked Structure of a Phospholipid Copolymer Film for Medical Devices","volume":"16","author":"Uchida","year":"2024","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.addr.2026.115773_bb0890","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/B978-0-12-805082-8.00002-5","article-title":"Sensitive combination products: Devices, pharmaceuticals, and biologics","author":"Lewis","year":"2020","journal-title":"Assurance of Sterility for Sensitive Combination Products and Materials"},{"key":"10.1016\/j.addr.2026.115773_bb0895","series-title":"Assurance of Sterility for Sensitive Combination Products and Materials, Academic Press","first-page":"5","article-title":"Chapter 2 - Sensitive combination products: Devices, pharmaceuticals, and biologics","author":"Lewis","year":"2020"},{"key":"10.1016\/j.addr.2026.115773_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2020.587352","article-title":"Medical Device Sterilization and Reprocessing in the Era of Multidrug-Resistant (MDR) Bacteria: Issues and Regulatory Concepts","volume":"2","author":"Josephs-Spaulding","year":"2021","journal-title":"Frontiers in Medical Technology"},{"key":"10.1016\/j.addr.2026.115773_bb0905","series-title":"Assurance of Sterility for Sensitive Combination Products and Materials, Academic Press","first-page":"39","article-title":"Chapter 4 - Aseptic processing","author":"Baseman","year":"2020"},{"key":"10.1016\/j.addr.2026.115773_bb0910","series-title":"Technical Report No. 22, Process Simulation for Aseptically Filled Products","author":"Parenteral Drug Association","year":"2011"},{"key":"10.1016\/j.addr.2026.115773_bb0915","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2022.10.009","article-title":"Surface-Induced Protein Aggregation and Particle Formation in Biologics: Current Understanding of Mechanisms, Detection and Mitigation Strategies","volume":"112","author":"Kopp","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0920","series-title":"Advances in Protein Chemistry, Academic Press 1970","first-page":"1","article-title":"starting on p. 121 Theoretical Models for The Mechanism of Denaturation","author":"Tanford","year":"1968"},{"key":"10.1016\/j.addr.2026.115773_bb0925","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1021\/jp906350s","article-title":"Urea-Mediated Protein Denaturation: A Consensus View","volume":"113","author":"Das","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.addr.2026.115773_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.03.041","article-title":"Nature and consequences of protein\u2013protein interactions in high protein concentration solutions","volume":"358","author":"Saluja","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2026.115773_bb0935","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.xphs.2021.09.030","article-title":"Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality","volume":"111","author":"Das","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb0940","unstructured":"YOUR GUIDE TO THE SUSVIMO\u00ae IMPLANT PROCEDURE."},{"key":"10.1016\/j.addr.2026.115773_bb0945","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/IAE.0000000000002614","article-title":"Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model","volume":"40","author":"Bantseev","year":"2020","journal-title":"RETINA"},{"key":"10.1016\/j.addr.2026.115773_bb0950","first-page":"266","article-title":"Conjunctiva and Tenon's Capsule Handling in the Port Delivery System with Ranibizumab Implant Insertion Procedure: Surgical Pearls, Ophthalmic Surgery, Lasers and Imaging","volume":"53","author":"Graff","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.addr.2026.115773_bb0955","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0960","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaophthalmol.2022.2495","article-title":"Ranibizumab Injection (Susvimo) Implant Septum Dislodgement in a Patient With Neovascular Age-Related Macular Degeneration","volume":"140","author":"Timmons","year":"2022","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.addr.2026.115773_bb0965","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.addr.2011.10.008","article-title":"Lessons from innovation in drug-device combination products","volume":"64","author":"Couto","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb0970","series-title":"Overcoming the challenges of regulating combination products","author":"Miermeister","year":"2022"},{"key":"10.1016\/j.addr.2026.115773_bb0975","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.821094","article-title":"The regulatory challenges of innovative customized combination products","volume":"9","author":"Reis","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.addr.2026.115773_bb0980","doi-asserted-by":"crossref","first-page":"27","DOI":"10.22270\/ijdra.v2i3.139","article-title":"Regulatory strategy for registration of combination products to US-FDA","volume":"2","author":"Vihar Kotha","year":"2014","journal-title":"Int J Drug Reg Affairs [Internet]"},{"key":"10.1016\/j.addr.2026.115773_bb0985","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/2168479017735142","article-title":"Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views","volume":"52","author":"Masterson","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.addr.2026.115773_bb0990","series-title":"Encyclopedia of Tissue Engineering and Regenerative Medicine","first-page":"207","article-title":"Regulation of Combination Products\u2014Evolving Landscape","author":"George","year":"2019"},{"key":"10.1016\/j.addr.2026.115773_bb0995","doi-asserted-by":"crossref","first-page":"235","DOI":"10.63001\/tbs.2025.v20.i03.S.I(3).pp235-241","article-title":"Comparison of Combination Product Regulations: Challenges and approval pathway in the US and Europe, The","volume":"20","author":"Madhavan","year":"2025","journal-title":"Bioscan"},{"key":"10.1016\/j.addr.2026.115773_bb1000","first-page":"796","article-title":"Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea, Therapeutic Innovation & Regulatory","volume":"58","author":"Kim","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.addr.2026.115773_bb1005","doi-asserted-by":"crossref","DOI":"10.1002\/psc.70001","article-title":"Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins","volume":"31","author":"Elsayed","year":"2025","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1015","unstructured":"Regulatory Stability Considerations for Biological Products."},{"key":"10.1016\/j.addr.2026.115773_bb1030","first-page":"6357","article-title":"Characterization of a Tailored Bi-Specific DutaFab, Zifibancimig, for Neutralizing Both VEGF-A and Ang-2, and Continuous Ocular Delivery","volume":"66","author":"Moelleken","year":"2025","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1035","series-title":"Zifibancimig Administered via Intravitreal Injection and the Port Delivery Platform in Patients With nAMD: Rationale and Design of the Burgundy Study","author":"Jeremy","year":"2025"},{"key":"10.1016\/j.addr.2026.115773_bb1040","series-title":"Characterization of a Tailored Bi-Specific DutaFab, Zifibancimig, for Neutralizing Both VEGF-A and Ang-2, and Continuous Ocular Delivery via the Port Delivery Platform","author":"Moelleken","year":"2025"},{"key":"10.1016\/j.addr.2026.115773_bb1045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2026.115773_bb1050","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.addr.2026.115773_bb1055","doi-asserted-by":"crossref","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115773_bb1060","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1065","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115773_bb1070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1075","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/hum.2019.337","article-title":"Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy","volume":"31","author":"Song","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.2019.297","article-title":"Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa","volume":"31","author":"Dufour","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.65.14.1","article-title":"Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies","volume":"65","author":"Calton","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In Vivo\u2013Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115773_bb1095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41434-021-00306-1","article-title":"Outer retinal transduction by AAV2-7m8 following intravitreal injection in a sheep model of CNGA3 achromatopsia","volume":"29","author":"Ross","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1100","article-title":"Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates","author":"Kotterman","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2026.115773_bb1105","article-title":"Dual AAV vectors for efficient delivery of large transgenes","author":"Mittas","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2026.115773_bb1110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/hgtb.2013.212","article-title":"Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A","volume":"25","author":"Dyka","year":"2014","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.addr.2026.115773_bb1115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2026.115773_bb1120","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/hmg\/ddae144","article-title":"Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system","volume":"33","author":"Datta","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2026.115773_bb1125","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1038\/s41467-023-42386-0","article-title":"mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy","volume":"14","author":"Riedmayr","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2026.115773_bb1130","doi-asserted-by":"crossref","first-page":"eaav4523","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115773_bb1135","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple Vectors Expand AAV Transfer Capacity in the Retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1140","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1093\/hmg\/ddv386","article-title":"Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease","volume":"24","author":"Trapani","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2026.115773_bb1145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2174\/187152811796117717","article-title":"Inflammation and immunology of the vitreoretinal compartment","volume":"10","author":"Boehm","year":"2011","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.addr.2026.115773_bb1150","doi-asserted-by":"crossref","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2026.115773_bb1155","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/molecules22071155","article-title":"Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity","volume":"22","author":"Yao","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2026.115773_bb1160","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/mt.2008.100","article-title":"Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles","volume":"16","author":"Li","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2026.115773_bb1165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2026.115773_bb1170","doi-asserted-by":"crossref","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2026.115773_bb1175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612976","article-title":"Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases","volume":"24","author":"Tsung","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/17425247.2016.1218460","article-title":"Minimally invasive microneedles for ocular drug delivery","volume":"14","author":"Thakur Singh","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2026.115773_bb1185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030734","article-title":"Updates on Biodegradable Formulations for Ocular Drug Delivery","volume":"15","author":"Tsung","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb1190","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071862","article-title":"Innovative Strategies for Drug Delivery to the Ocular Posterior Segment","volume":"15","author":"Gabai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2026.115773_bb1195","article-title":"Serum-PEG and BSA-PEG hydrogels as advanced platforms for evaluating plasma protein binding","volume":"45","author":"Coelho","year":"2025","journal-title":"Mater. Today Chem."},{"key":"10.1016\/j.addr.2026.115773_bb1200","first-page":"1","article-title":"BSA-PEG Hydrogel: A Novel Protein-Ligand Binding 3D Matrix","volume":"11","author":"Coelho","year":"2022","journal-title":"Medical Sciences Forum"},{"key":"10.1016\/j.addr.2026.115773_bb1205","first-page":"64","article-title":"A Comprehensive Review of Hydrogel-Based Drug Delivery Systems: Classification","volume":"25","author":"Hameed","year":"2024","journal-title":"Properties, Recent Trends, and Applications, AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2026.115773_bb1210","article-title":"Emerging hydrogel therapies for translating brain disease: Materials, mechanisms, and recent research","volume":"22","author":"Lu","year":"2024","journal-title":"Mater. Today Adv."},{"key":"10.1016\/j.addr.2026.115773_bb1215","doi-asserted-by":"crossref","first-page":"2205037","DOI":"10.1002\/advs.202205037","article-title":"The Impact of the Cellular Environment and Aging on Modeling Alzheimer's Disease in 3D Cell Culture Models","volume":"10","author":"Hebisch","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mser.2015.04.001","article-title":"Stimulus-responsive hydrogels: Theory, modern advances, and applications","volume":"93","author":"Koetting","year":"2015","journal-title":"Mater. Sci. Eng. R. Rep."},{"key":"10.1016\/j.addr.2026.115773_bb1225","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1021\/acs.biomac.2c00383","article-title":"Hyaluronic Acid-PEG-Based Diels\u2013Alder In Situ Forming Hydrogels for Sustained Intraocular Delivery of Bevacizumab","volume":"23","author":"Ilochonwu","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2026.115773_bb1230","doi-asserted-by":"crossref","DOI":"10.1115\/1.4048481","article-title":"Hydrogel-Forming Microneedle Arrays for Sustained and Controlled Ocular Drug Delivery","volume":"3","author":"Amer","year":"2020","journal-title":"Journal of Engineering and Science in Medical Diagnostics and Therapy"},{"key":"10.1016\/j.addr.2026.115773_bb1235","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2014.00085","article-title":"Autologous fibrin glue as an encapsulating scaffold for delivery of retinal progenitor cells","author":"Ahmed","year":"2015","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"10.1016\/j.addr.2026.115773_bb1240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227641","article-title":"Fibrin hydrogels are safe, degradable scaffolds for sub-retinal implantation","volume":"15","author":"Gandhi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2026.115773_bb1245","article-title":"Diabetic Retinopathy: Pathophysiology and Treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1250","doi-asserted-by":"crossref","DOI":"10.3390\/cells14050376","article-title":"Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies","volume":"14","author":"Seo","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.addr.2026.115773_bb1255","doi-asserted-by":"crossref","DOI":"10.2174\/0115733998240053231009060654","article-title":"Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy","volume":"20","author":"Parashar","year":"2024","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.addr.2026.115773_bb1260","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/17425247.2024.2431577","article-title":"Advanced drug delivery strategies for diabetic retinopathy: current therapeutic advancement, and delivery methods overcoming barriers, and experimental modalities","volume":"21","author":"Diress","year":"2024","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.addr.2026.115773_bb1265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051828","article-title":"The Global Burden of Glaucoma: Findings from the Global Burden of Disease 2019 Study and Predictions by Bayesian Age-Period-Cohort Analysis","volume":"12","author":"Lin","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2026.115773_bb1270","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.addr.2026.115773_bb1275","first-page":"164","article-title":"Glaucoma in Adults-Screening","volume":"325","author":"Stein","year":"2021","journal-title":"Diagnosis, and Management: A Review, Jama"},{"key":"10.1016\/j.addr.2026.115773_bb1280","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.tips.2023.09.010","article-title":"Glaucoma: neuroprotection with NAD-based therapeutic interventions","volume":"44","author":"Chiarugi","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2026.115773_bb1285","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","article-title":"Glaucoma: now and beyond","volume":"402","author":"Jayaram","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2026.115773_bb1290","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.addr.2026.115773_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118319","article-title":"Integrating neuroprotection, antioxidative effects, and precision medicine in glaucoma management with bioactive compounds","volume":"190","author":"Zhu","year":"2025","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.addr.2026.115773_bb1300","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.actbio.2013.11.004","article-title":"A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye","volume":"10","author":"Nagai","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2026.115773_bb1305","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s13346-021-00930-9","article-title":"Co-delivery of glial cell\u2013derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases","volume":"11","author":"Arranz-Romera","year":"2021","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.addr.2026.115773_bb1310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023044057","article-title":"Current Insights into Targeting Strategies for the Effective Therapy of Diseases of the Posterior Eye Segment","volume":"41","author":"Pimple","year":"2024","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.addr.2026.115773_bb1315","first-page":"eaba3252","article-title":"Wireless smart contact lens for diabetic diagnosis and therapy, Science","volume":"6","author":"Keum","year":"2020","journal-title":"Advances"},{"key":"10.1016\/j.addr.2026.115773_bb1320","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114817","article-title":"Smart contact lens systems for ocular drug delivery and therapy","volume":"196","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2026.115773_bb1325","doi-asserted-by":"crossref","first-page":"45789","DOI":"10.1021\/acsami.0c12667","article-title":"Soft Contact Lens with Embedded Microtubes for Sustained and Self-Adaptive Drug Delivery for Glaucoma Treatment","volume":"12","author":"Ding","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2026.115773_bb1330","doi-asserted-by":"crossref","first-page":"2112508","DOI":"10.1002\/adfm.202112508","article-title":"Reconfigurable Magnetic Slime Robot: Deformation, Adaptability, and Multifunction","volume":"32","author":"Sun","year":"2022","journal-title":"Adv. Funct. Mater."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X26000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:34:02Z","timestamp":1782189242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X26000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":259,"alternative-id":["S0169409X26000074"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2026.115773","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2026.115773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115773"}}